
Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings
In an exclusive interview with Psychiatric Times, Peter J. Weiden, MD, clinical professor of psychiatry at SUNY Stony Brook, offered key clinical insights into the recently released study results evaluating Cobenfy (xanomeline/trospium) as an adjunct …